Inflammatory mediators and signaling proteins

Inflammatory mediators and signaling proteins represent a broad and heterogeneous category of molecules that orchestrate the body's response to injury and infection. This group includes secreted factors such as cytokines, chemokines, and lipid mediators like prostaglandins, as well as the intracellular signaling pathways they activate, such as the JAK-STAT and NF-kappaB cascades (StatPearls: Inflammation). While these molecules are essential for normal immune function and tissue repair, their chronic or excessive production is a hallmark of numerous pathologies, including rheumatoid arthritis, inflammatory bowel disease, and various cancers (Nature: Signaling in Inflammation). Pharmacological intervention often focuses on specific members of this group, such as TNF-alpha or Janus kinases, to alleviate symptoms and prevent tissue damage in autoimmune and inflammatory conditions (PubMed: Therapeutic targeting of inflammation). Because this term encompasses hundreds of distinct proteins with diverse functions, it serves as a functional classification rather than a single, well-defined therapeutic target. Drugs targeting these pathways, such as monoclonal antibodies or small molecule inhibitors, are among the most successful therapeutics in modern medicine for managing chronic disease. However, systemic inhibition of these mediators can lead to significant safety concerns, primarily an increased susceptibility to infections due to suppressed immune surveillance.

Other names

Inflammatory signaling moleculesPro-inflammatory mediatorsCytokines and chemokinesInflammatory cascade components

Drugs targeting these pathways typically act by neutralizing circulating ligands, blocking cell-surface receptors, or inhibiting intracellular signaling enzymes to dampen the inflammatory cascade.